LEADER 03905nam  22006853u 450 
001 996339091403316
005 20230617001213.0
010   $a1-280-30995-4
010   $a9786610309955
010   $a1-84692-543-6
035   $a(CKB)1000000000463452
035   $a(EBL)362704
035   $a(OCoLC)437229078
035   $a(SSID)ssj0000258331
035   $a(PQKBManifestationID)12078600
035   $a(PQKBTitleCode)TC0000258331
035   $a(PQKBWorkID)10256451
035   $a(PQKB)10149255
035   $a(MiAaPQ)55150
035   $a(EXLCZ)991000000000463452
100   $a20130418d2005||||  u||            |
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aTherapeutic Strategies in Thrombosis$b[electronic resource]
210   $aOxford $cAtlas Medical Publishing Ltd$d2005
215   $a1 online resource (405 p.)
225 1 $aTherapeutic Strategies
300   $aDescription based upon print version of record.
311   $a1-904392-34-2 
327   $aContents; Contributors; 1. Arterial thrombosis: a brief overview; 2. Aspirin: a risk-based strategy; 3. Clopidogrel and other platelet ADP inhibitors; 4. Glycoprotein IIb/IIIa inhibitors; 5. Unfractionated heparin and low-molecular-weight heparin in coronary heart disease; 6. Intravenous direct thrombin inhibition: acute coronary syndromes and heparin-induced thrombocytopaenia; 7. Direct thrombin inhibition during percutaneous coronary interventions; 8. Pentasaccharide and other factor Xa inhibitors
327   $a9. Direct thrombin inhibition - thromboprophylaxis, deep venous thrombosis, atrial fibrillation and coronary artery disease10. Warfarin after acute myocardial infarction; 11. Thrombolytic therapy and concomitantantithrombotic therapy; 12. Pre-hospital reperfusion therapy; 13. Antithrombotic strategies in patients undergoing primary percutaneous intervention; 14. Antithrombotic management in patients with prosthetic valves; 15. Stroke: thrombolysis and antithrombotic therapy; 16. Atrial fibrillation: antithrombotic therapy; 17, Venous thromboembolism: pathophysiology and diagnosis
327   $a18. Antithrombotic therapy in venous thrombosis and pulmonary embolism19.Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, hypercoagulable states, pregnancy and renal diseases; 20. Monitoring of antithrombotic drugs; Index
330   $aIn this new volume, leading authorities from around the world provide an evidence-based review of the therapeutic options currently available for the management of thrombosis. Topics covered include the use of aspirin for primary and secondary prophylaxis, platelet inhibitors, glycoprotein IIb and IIa inhibitors, pentasaccharides, warfarin, and other agents. Other sections discuss the implementation of antithrombotic therapy in managing specific clinical conditions such as pulmonary embolism, atrial fibrillation, stroke and diabetes, or as an adjunct to other procedures such as PCI.
410  0$aTherapeutic Strategies
606   $aThrombolytic therapy
606   $aThrombosis -- Treatment
606   $aThrombosis
606   $aCardiovascular Diseases$2HILCC
606   $aMedicine$2HILCC
606   $aHealth & Biological Sciences$2HILCC
615  4$aThrombolytic therapy.
615  4$aThrombosis -- Treatment.
615  4$aThrombosis.
615  7$aCardiovascular Diseases
615  7$aMedicine
615  7$aHealth & Biological Sciences
676   $a616.13506
700   $aKristensen$b S. D.$f1955-$01019084
701   $aDe Caterina$b R.$f1954-$0602130
701   $aMoliterno$b David J$0893157
801  0$bAU-PeEL
801  1$bAU-PeEL
801  2$bAU-PeEL
906   $aBOOK
912   $a996339091403316
996   $aTherapeutic Strategies in Thrombosis$92400581
997   $aUNISA